References
- who.int [homepage on the Internet]Hepatitis C. Fact sheet 164World Health Organization2015 Available from: http://www.who.int/mediacentre/factsheets/fs164/en/Accessed April 21, 2016
- FriedMWShiffmanMLReddyKRPeginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionN Engl J Med20023471397598212324553
- MannsMPMcHutchisonJGGordonSCPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialLancet2001358928695896511583749
- AsselahTBoyerNSaadounDMartinot-PeignouxMMarcellinPDirect-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectivesLiver Int201636Suppl 1475726725897
- WedemeyerHTowards interferon-free treatment for all HCV genotypesLancet201538599862443244525837828
- hcvguidelines.org [homepage on the Internet]Initial treatment of hcv infectionAmerican Association for the Study of Liver Diseases and the Infectious Diseases Society of America [updated February 24, 2016]. Available from: http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infectionAccessed April 22, 2016
- AbbVie CorporationProduct monograph including patient medication information PrHOLKIRA™ PAKAbbVie Corporation2016 Available from: http://www.abbvie.ca/content/dam/abbviecorp/ca/english/docs/HOLKIRA_PAK_PM_EN.pdfAccessed April 22, 2016
- KhatriAMenonRMMarburyTCPharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairmentJ Hepatol201563480581226070406
- MenonRMBadriPSWangTDrug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvirJ Hepatol2015631202925646891
- BurgessSPartoviNYoshidaEMErbSRAzalgaraVMHussainiTDrug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patientsAnn Pharmacother201549667468725770114
- FeldJJKowdleyKVCoakleyETreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinN Engl J Med2014370171594160324720703
- FerenciPBernsteinDLalezariJABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCVN Engl J Med2014370211983199224795200
- ZeuzemSJacobsonIMBaykalTRetreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinN Engl J Med2014370171604161424720679
- AndreonePColomboMGEnejosaJVABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infectionGastroenterology20141472359365.e124818763
- PoordadFHezodeCTrinhRABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosisN Engl J Med2014370211973198224725237
- FeldJJMorenoCTrinhRSustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeksJ Hepatol201664230130726476290
- SulkowskiMSEronJJWylesDOmbitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trialJAMA2015313121223123125706092
- KwoPYMantryPSCoakleyEAn interferon-free antiviral regimen for HCV after liver transplantationN Engl J Med2014371252375238225386767
- HézodeCAsselahTReddyKROmbitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trialLancet201538599862502250925837829
- PockrosPJReddyKRMantryPSRUBY-I: Ombitasvir/paritaprevir/ritonavir + dasabuvir +/− ribavirin in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal diseaseHepatology conference: 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver MeetingNov 13–19, 2015San Francisco, CA201562716A717A
- PockrosPJReddyKRMantryPSLO1: Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I studyJ Hepatol201562Suppl 2S257
- RothDNelsonDRBruchfeldAGrazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyLancet2015386100031537154526456905
- MaruyamaAPartoviNYoshidaEMErbSRAzalgaraVMHussainiTA review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney diseaseNephrol Dial Transplant Epub20151019
- FeldJJJacobsonIMHezodeCSofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infectionN Engl J Med2015373272599260726571066
- FosterGRAfdhalNRobertsSKSofosbuvir and velpatasvir for HCV genotype 2 and 3 infectionN Engl J Med2015373272608261726575258